Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 71


Synthetic lethal screen identification of chemosensitizer loci in cancer cells.

Whitehurst AW, Bodemann BO, Cardenas J, Ferguson D, Girard L, Peyton M, Minna JD, Michnoff C, Hao W, Roth MG, Xie XJ, White MA.

Nature. 2007 Apr 12;446(7137):815-9.


Mechanisms promoting escape from mitotic stress-induced tumor cell death.

Sinnott R, Winters L, Larson B, Mytsa D, Taus P, Cappell KM, Whitehurst AW.

Cancer Res. 2014 Jul 15;74(14):3857-69. doi: 10.1158/0008-5472.CAN-13-3398.


Symplekin specifies mitotic fidelity by supporting microtubule dynamics.

Cappell KM, Larson B, Sciaky N, Whitehurst AW.

Mol Cell Biol. 2010 Nov;30(21):5135-44. doi: 10.1128/MCB.00758-10.


Genome-wide siRNA-based functional genomics of pigmentation identifies novel genes and pathways that impact melanogenesis in human cells.

Ganesan AK, Ho H, Bodemann B, Petersen S, Aruri J, Koshy S, Richardson Z, Le LQ, Krasieva T, Roth MG, Farmer P, White MA.

PLoS Genet. 2008 Dec;4(12):e1000298. doi: 10.1371/journal.pgen.1000298.


Gene expression and mitotic exit induced by microtubule-stabilizing drugs.

Chen JG, Yang CP, Cammer M, Horwitz SB.

Cancer Res. 2003 Nov 15;63(22):7891-9.


Multiple cancer testis antigens function to support tumor cell mitotic fidelity.

Cappell KM, Sinnott R, Taus P, Maxfield K, Scarbrough M, Whitehurst AW.

Mol Cell Biol. 2012 Oct;32(20):4131-40.


Synergistic suppression of microtubule dynamics by discodermolide and paclitaxel in non-small cell lung carcinoma cells.

Honore S, Kamath K, Braguer D, Horwitz SB, Wilson L, Briand C, Jordan MA.

Cancer Res. 2004 Jul 15;64(14):4957-64.


A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel.

Du L, Borkowski R, Zhao Z, Ma X, Yu X, Xie XJ, Pertsemlidis A.

RNA Biol. 2013 Nov;10(11):1700-13. doi: 10.4161/rna.26541.


Rational design of cancer-drug combinations.

Ramaswamy S.

N Engl J Med. 2007 Jul 19;357(3):299-300. No abstract available.


Resistance to Taxol in lung cancer cells associated with increased microtubule dynamics.

Gonçalves A, Braguer D, Kamath K, Martello L, Briand C, Horwitz S, Wilson L, Jordan MA.

Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11737-42.


Nakiterpiosin targets tubulin and triggers mitotic catastrophe in human cancer cells.

Wei JH, Seemann J.

Mol Cancer Ther. 2010 Dec;9(12):3375-85. doi: 10.1158/1535-7163.MCT-10-0305.


Orally active microtubule-targeting agent, MPT0B271, for the treatment of human non-small cell lung cancer, alone and in combination with erlotinib.

Tsai AC, Wang CY, Liou JP, Pai HC, Hsiao CJ, Chang JY, Wang JC, Teng CM, Pan SL.

Cell Death Dis. 2014 Apr 10;5:e1162. doi: 10.1038/cddis.2014.128.


Tubulin-targeted drug action: functional significance of class ii and class IVb beta-tubulin in vinca alkaloid sensitivity.

Gan PP, Kavallaris M.

Cancer Res. 2008 Dec 1;68(23):9817-24. doi: 10.1158/0008-5472.CAN-08-1501.


Tumor antigen acrosin binding protein normalizes mitotic spindle function to promote cancer cell proliferation.

Whitehurst AW, Xie Y, Purinton SC, Cappell KM, Swanik JT, Larson B, Girard L, Schorge JO, White MA.

Cancer Res. 2010 Oct 1;70(19):7652-61. doi: 10.1158/0008-5472.CAN-10-0840.


Identification of chemosensitivity nodes for vinblastine through small interfering RNA high-throughput screens.

Kitchens CA, McDonald PR, Shun TY, Pollack IF, Lazo JS.

J Pharmacol Exp Ther. 2011 Dec;339(3):851-8. doi: 10.1124/jpet.111.184879.


MISSION LentiPlex pooled shRNA library screening in mammalian cells.

Coussens MJ, Corman C, Fischer AL, Sago J, Swarthout J.

J Vis Exp. 2011 Dec 21;(58). pii: 3305. doi: 10.3791/3305.


The inhibition of Aurora A abrogates the mitotic delay induced by microtubule perturbing agents.

Wysong DR, Chakravarty A, Hoar K, Ecsedy JA.

Cell Cycle. 2009 Mar 15;8(6):876-88.


Microtubule dynamics, mitotic arrest, and apoptosis: drug-induced differential effects of betaIII-tubulin.

Gan PP, McCarroll JA, Po'uha ST, Kamath K, Jordan MA, Kavallaris M.

Mol Cancer Ther. 2010 May;9(5):1339-48. doi: 10.1158/1535-7163.MCT-09-0679.

Supplemental Content

Support Center